Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Han, Bing  [Clear All Filters]
2024
Zhang Z, Hu Q, Yang C, Chen M, Han B. Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes. Ann Hematol. 2024.
Lan X, Zhang F, Yang C, Su W, Du JH, Liu S, Chen M, Han B, Zhou D, Zhuang J. Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone. Chronic Dis Transl Med. 2024;10(1):62-68.
Zhu W, Du W, Duan R, Liu Y, Zong B, Jin X, Dong Z, Wang H, Shahab S, Wang H, et al. miR-873-5p Suppression Reinvigorates Aging Mesenchymal Stem Cells and Improves Cardiac Repair after Myocardial Infarction. ACS Pharmacol Transl Sci. 2024;7(3):743-756.
de Latour RPeffault, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994-1008.
Jin X, Jiang X, Li H, Shen KN, Liu S, Chen M, Yang C, Han B, Zhuang J. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria. Acta Haematol. 2024.
Sui H, Deng W, Chai Q, Han B, Zhang Y, Wei Z, Li Z, Wang T, Feng J, Yuan M, et al. YTE-17 inhibits colonic carcinogenesis by resetting antitumor immune response via Wnt5a/JNK mediated metabolic signaling. J Pharm Anal. 2024;14(4):100901.